Published in Ann Intern Med on July 01, 2008
Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity | NCT02445989
The human vaginal bacterial biota and bacterial vaginosis. Interdiscip Perspect Infect Dis (2009) 2.56
The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG (2011) 2.41
Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR. J Clin Microbiol (2009) 2.29
Characteristic male urine microbiomes associate with asymptomatic sexually transmitted infection. PLoS One (2010) 2.02
Quantitative PCR assessments of bacterial species in women with and without bacterial vaginosis. J Clin Microbiol (2010) 1.69
Community analysis of chronic wound bacteria using 16S rRNA gene-based pyrosequencing: impact of diabetes and antibiotics on chronic wound microbiota. PLoS One (2009) 1.68
Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis (2010) 1.59
Genomic determinants of sporulation in Bacilli and Clostridia: towards the minimal set of sporulation-specific genes. Environ Microbiol (2012) 1.59
Interpreting the epidemiology and natural history of bacterial vaginosis: are we still confused? Anaerobe (2011) 1.50
The vaginal microbiota: what have we learned after a decade of molecular characterization? PLoS One (2014) 1.43
Analysis of adherence, biofilm formation and cytotoxicity suggests a greater virulence potential of Gardnerella vaginalis relative to other bacterial-vaginosis-associated anaerobes. Microbiology (2009) 1.35
The vaginal microbiota of pregnant women who subsequently have spontaneous preterm labor and delivery and those with a normal delivery at term. Microbiome (2014) 1.35
Identification of rhesus macaque genital microbiota by 16S pyrosequencing shows similarities to human bacterial vaginosis: implications for use as an animal model for HIV vaginal infection. AIDS Res Hum Retroviruses (2010) 1.29
Differences in vaginal microbiome in African American women versus women of European ancestry. Microbiology (2014) 1.20
Understanding vaginal microbiome complexity from an ecological perspective. Transl Res (2012) 1.19
Metabolic signatures of bacterial vaginosis. MBio (2015) 1.18
The complex vaginal flora of West African women with bacterial vaginosis. PLoS One (2011) 1.13
Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study. PLoS One (2010) 1.08
Emerging Sexual Health Issues Among Women Who Have Sex with Women. Curr Infect Dis Rep (2012) 1.02
Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis (2012) 1.00
Altered biomarkers of mucosal immunity and reduced vaginal Lactobacillus concentrations in sexually active female adolescents. PLoS One (2012) 0.98
The Human Microbiome during Bacterial Vaginosis. Clin Microbiol Rev (2016) 0.91
Comparative genomics of Lactobacillus crispatus suggests novel mechanisms for the competitive exclusion of Gardnerella vaginalis. BMC Genomics (2014) 0.86
Longitudinal analysis of vaginal microbiome dynamics in women with recurrent bacterial vaginosis: recognition of the conversion process. PLoS One (2013) 0.86
Making inroads into improving treatment of bacterial vaginosis - striving for long-term cure. BMC Infect Dis (2015) 0.84
The posttrial effect of oral periodic presumptive treatment for vaginal infections on the incidence of bacterial vaginosis and Lactobacillus colonization. Sex Transm Dis (2012) 0.83
Effect of sexual activity on vaginal colonization with hydrogen peroxide-producing lactobacilli and Gardnerella vaginalis. Sex Transm Dis (2011) 0.82
Relationship of Specific Bacteria in the Cervical and Vaginal Microbiotas With Cervicitis. Sex Transm Dis (2015) 0.81
Effect of sexual debut on vaginal microbiota in a cohort of young women. Obstet Gynecol (2012) 0.81
Anaerobes and bacterial vaginosis in pregnancy: virulence factors contributing to vaginal colonisation. Int J Environ Res Public Health (2014) 0.80
A behavioural intervention to reduce persistence of bacterial vaginosis among women who report sex with women: results of a randomised trial. Sex Transm Infect (2011) 0.80
Behavioral predictors of colonization with Lactobacillus crispatus or Lactobacillus jensenii after treatment for bacterial vaginosis: a cohort study. Infect Dis Obstet Gynecol (2012) 0.79
Evidence for Gardnerella vaginalis uptake and internalization by squamous vaginal epithelial cells: implications for the pathogenesis of bacterial vaginosis. Microbes Infect (2011) 0.79
Generation of recombinant single-chain antibodies neutralizing the cytolytic activity of vaginolysin, the main virulence factor of Gardnerella vaginalis. BMC Biotechnol (2011) 0.78
Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation. J Infect Dis (2016) 0.78
Factors Associated with Bacterial Vaginosis among Women Who Have Sex with Women: A Systematic Review. PLoS One (2015) 0.77
Molecular analysis of the relationship between specific vaginal bacteria and bacterial vaginosis metronidazole therapy failure. Eur J Clin Microbiol Infect Dis (2014) 0.76
Persistent microbial dysbiosis in preterm premature rupture of membranes from onset until delivery. PeerJ (2015) 0.76
Tinidazole in the treatment of bacterial vaginosis. Int J Womens Health (2010) 0.76
Clinical pearls in infectious diseases. Mayo Clin Proc (2010) 0.75
Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol (1991) 20.49
Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med (1983) 16.63
Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med (2005) 11.23
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis (2006) 5.96
Vaginitis. N Engl J Med (1997) 5.30
The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis (2007) 3.93
Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis (2005) 3.50
Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol (2003) 3.36
Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol (2007) 3.10
Quantitation of BK virus load in serum for the diagnosis of BK virus-associated nephropathy in renal transplant recipients. J Infect Dis (2001) 2.79
Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis (2004) 2.67
Proposal of the genera Anaerococcus gen. nov., Peptoniphilus gen. nov. and Gallicola gen. nov. for members of the genus Peptostreptococcus. Int J Syst Evol Microbiol (2001) 2.59
Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol (2006) 2.56
Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis (2002) 2.09
An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol (2007) 2.04
Metronidazole. A therapeutic review and update. Drugs (1997) 1.87
Curved anaerobic bacteria in bacterial (nonspecific) vaginosis and their response to antimicrobial therapy. J Infect Dis (1983) 1.77
Gynecologic conditions and bacterial vaginosis: implications for the non-pregnant patient. Infect Dis Obstet Gynecol (2000) 1.74
Bacterial vaginosis: efficacy and safety of intravaginal metronidazole treatment. Am J Obstet Gynecol (1994) 1.72
Paraffin removal from tissue sections for digestion and PCR analysis. Biotechniques (1999) 1.66
Risk factors for bacterial vaginosis in women at high risk for sexually transmitted diseases. Sex Transm Dis (2005) 1.56
The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J Infect Dis (2006) 1.55
Antibiotic susceptibility of Atopobium vaginae. BMC Infect Dis (2006) 1.30
Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis. Obstet Gynecol (1993) 1.28
Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol (2004) 1.24
Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol (2004) 1.20
Molecular methodology in determining vaginal flora in health and disease: its time has come. Curr Infect Dis Rep (2005) 1.14
Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis. Sex Transm Dis (1999) 1.11
Rapid identification of Gram-positive anaerobic coccal species originally classified in the genus Peptostreptococcus by multiplex PCR assays using genus- and species-specific primers. Microbiology (2003) 1.04
Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy. J Reprod Med (2000) 0.97
The effect of treatment regimens for vaginitis and cervicitis on vaginal colonization by lactobacilli. Sex Transm Dis (1996) 0.93
Vaginal flora morphotypic profiles and assessment of bacterial vaginosis in women at risk for HIV infection. Infect Dis Obstet Gynecol (2005) 0.92
The effects of intravaginal clindamycin and metronidazole therapy on vaginal mobiluncus morphotypes in patients with bacterial vaginosis. Sex Transm Dis (2007) 0.92
Antimicrobial susceptibility of comma-shaped bacteria isolated from the vagina. Scand J Infect Dis Suppl (1983) 0.89
The effects of intravaginal clindamycin and metronidazole therapy on vaginal lactobacilli in patients with bacterial vaginosis. Am J Obstet Gynecol (2006) 0.84
Plasmid analysis and antimicrobial susceptibilities of Peptostreptococcus species. FEMS Microbiol Lett (1989) 0.78
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90
Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med (2005) 11.23
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med (2005) 3.96
Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol (2007) 3.10
Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med (2006) 2.85
Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS One (2012) 2.79
Diversity of human vaginal bacterial communities and associations with clinically defined bacterial vaginosis. Appl Environ Microbiol (2008) 2.73
Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. PLoS One (2010) 2.62
The human vaginal bacterial biota and bacterial vaginosis. Interdiscip Perspect Infect Dis (2009) 2.56
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44
Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis (2004) 2.31
Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR. J Clin Microbiol (2009) 2.29
HIV testing in a high-incidence population: is antibody testing alone good enough? Clin Infect Dis (2009) 2.23
Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis (2013) 2.18
Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis (2011) 1.94
Development and optimization of quantitative PCR for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. BMC Infect Dis (2008) 1.70
Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. Clin Infect Dis (2012) 1.67
Determinants of recent HIV infection among Seattle-area men who have sex with men. Am J Public Health (2008) 1.61
Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis (2010) 1.59
Cultivation of Tropheryma whipplei from cerebrospinal fluid. J Infect Dis (2003) 1.58
Using nurses to identify HAART eligible patients in the Republic of Mozambique: results of a time series analysis. Hum Resour Health (2007) 1.51
Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure. PLoS One (2011) 1.35
Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med (2014) 1.24
PCR-based diagnosis of human fungal infections. Expert Rev Anti Infect Ther (2009) 1.24
Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol (2004) 1.20
Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS (2013) 1.19
Comparison of quantitative real time PCR with Sequencing and ribosomal RNA-FISH for the identification of fungi in formalin fixed, paraffin-embedded tissue specimens. BMC Infect Dis (2011) 1.14
Delay of antiretroviral therapy initiation is common in East African HIV-infected individuals in serodiscordant partnerships. J Acquir Immune Defic Syndr (2014) 1.09
Prevalence and risks for bacterial vaginosis in women who have sex with women. Sex Transm Dis (2010) 1.09
Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study. PLoS One (2010) 1.08
More than meets the eye: associations of vaginal bacteria with gram stain morphotypes using molecular phylogenetic analysis. PLoS One (2013) 1.07
Comparison of oral and vaginal metronidazole for treatment of bacterial vaginosis in pregnancy: impact on fastidious bacteria. BMC Infect Dis (2009) 1.07
Sequencing and analysis of fungal rRNA operons for development of broad-range fungal PCR assays. Appl Environ Microbiol (2009) 1.06
Performance of a new, rapid assay for detection of Trichomonas vaginalis. J Clin Microbiol (2004) 1.05
Partner characteristics predicting HIV-1 set point in sexually acquired HIV-1 among African seroconverters. AIDS Res Hum Retroviruses (2013) 1.02
Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis (2012) 1.00
Lactobacillus proteins are associated with the bactericidal activity against E. coli of female genital tract secretions. PLoS One (2012) 0.99
An intervention to support HIV preexposure prophylaxis adherence in HIV-serodiscordant couples in Uganda. J Acquir Immune Defic Syndr (2014) 0.98
Altered biomarkers of mucosal immunity and reduced vaginal Lactobacillus concentrations in sexually active female adolescents. PLoS One (2012) 0.98
Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis (2013) 0.97
Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy. AIDS (2015) 0.97
Expedited partner therapy: a robust intervention. Sex Transm Dis (2010) 0.88
Early pregnancy changes in bacterial vaginosis-associated bacteria and preterm delivery. Paediatr Perinat Epidemiol (2014) 0.88
Preterm labor and bacterial vaginosis-associated bacteria among urban women. J Perinat Med (2009) 0.87
Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive. PLoS One (2012) 0.87
Topical penile microbicide use by men to prevent recurrent bacterial vaginosis in sex partners: a randomized clinical trial. Sex Transm Dis (2011) 0.86
Changes in Vaginal Microbiota and Immune Mediators in HIV-1-Seronegative Kenyan Women Initiating Depot Medroxyprogesterone Acetate. J Acquir Immune Defic Syndr (2016) 0.85
Bacterial vaginosis-associated bacteria in men: association of Leptotrichia/Sneathia spp. with nongonococcal urethritis. Sex Transm Dis (2013) 0.84
Reduced adipogenic gene expression in thigh adipose tissue precedes human immunodeficiency virus-associated lipoatrophy. J Clin Endocrinol Metab (2007) 0.83
Effect of sexual activity on vaginal colonization with hydrogen peroxide-producing lactobacilli and Gardnerella vaginalis. Sex Transm Dis (2011) 0.82
Cervical shedding of human T cell lymphotropic virus type I is associated with cervicitis. J Infect Dis (2002) 0.82
Chlamydia positivity in women screened in family planning clinics: racial/ethnic differences and trends in the northwest U.S., 1997-2006. Public Health Rep (2012) 0.81
Effect of sexual debut on vaginal microbiota in a cohort of young women. Obstet Gynecol (2012) 0.81
Effects of bacterial vaginosis-associated bacteria and sexual intercourse on vaginal colonization with the probiotic Lactobacillus crispatus CTV-05. Sex Transm Dis (2011) 0.80
Associations between vaginal bacteria and levels of vaginal defensins in pregnant women. Am J Obstet Gynecol (2012) 0.80
A behavioural intervention to reduce persistence of bacterial vaginosis among women who report sex with women: results of a randomised trial. Sex Transm Infect (2011) 0.80
Human herpesvirus 8 and sarcoidosis. Clin Infect Dis (2002) 0.80
Enhanced fungal DNA-extraction from formalin-fixed, paraffin-embedded tissue specimens by application of thermal energy. Med Mycol (2012) 0.80
Behavioral predictors of colonization with Lactobacillus crispatus or Lactobacillus jensenii after treatment for bacterial vaginosis: a cohort study. Infect Dis Obstet Gynecol (2012) 0.79
A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. AIDS (2016) 0.79
Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation. AIDS (2016) 0.78
Relationship of selected bacterial vaginosis-associated bacteria to Nugent score bacterial vaginosis among urban women early in pregnancy. Sex Transm Dis (2013) 0.77
Detection of hydrogen peroxide-producing Lactobacillus species in the vagina: a comparison of culture and quantitative PCR among HIV-1 seropositive women. BMC Infect Dis (2012) 0.77
Herpes Simplex Virus Suppressive Therapy in Herpes Simplex Virus-2/Human Immunodeficiency Virus-1 Coinfected Women Is Associated With Reduced Systemic CXCL10 But Not Genital Cytokines. Sex Transm Dis (2016) 0.75
Semen Bacterial Concentrations and HIV-1 RNA Shedding among HIV-1-Seropositive Kenyan Men. J Acquir Immune Defic Syndr (2016) 0.75
Antiretroviral Therapy Initiation Is Not Associated With Risky Sexual Behavior Among Heterosexual Human Immunodeficiency Virus-Infected Persons in Serodiscordant Partnerships. Sex Transm Dis (2017) 0.75
Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection. J Acquir Immune Defic Syndr (2016) 0.75
Brief Report: Hormonal Contraception Is Not Associated With Reduced ART Effectiveness Among Women Initiating ART: Evidence From Longitudinal Data. J Acquir Immune Defic Syndr (2017) 0.75
Vaginal microbiota and genitourinary menopausal symptoms: a cross-sectional analysis. Menopause (2017) 0.75
Safety, acceptability, and tolerability of 3 topical microbicides among heterosexual Kenyan men. J Acquir Immune Defic Syndr (2007) 0.75